These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
2253 related items for PubMed ID: 16279901
1. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, Sharma BC. Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901 [Abstract] [Full Text] [Related]
2. Combination of pegylated interferon and lamivudine for patients with chronic hepatitis B who have failed treatment. Sarin SK, Kumar M, Hissar S, Sharma BC. Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):374-80. PubMed ID: 16911934 [Abstract] [Full Text] [Related]
5. Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial. Karabay O, Tamer A, Tahtaci M, Vardi S, Celebi H. J Microbiol Immunol Infect; 2005 Aug; 38(4):262-6. PubMed ID: 16118673 [Abstract] [Full Text] [Related]
8. Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT*. Sarin SK, Sandhu BS, Sharma BC, Jain M, Singh J, Malhotra V. J Viral Hepat; 2004 Nov; 11(6):552-8. PubMed ID: 15500556 [Abstract] [Full Text] [Related]
9. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN, Asia Hepatitis Lamivudine Study Group. Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543 [Abstract] [Full Text] [Related]
11. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels. Tseng TC, Liu CJ, Wang CC, Chen PJ, Lai MY, Chen DS, Kao JH. Antivir Ther; 2009 Oct; 14(2):203-10. PubMed ID: 19430095 [Abstract] [Full Text] [Related]
12. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B. Yao GB, Cui ZY, Wang BE, Yao JL, Zeng MD. Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107 [Abstract] [Full Text] [Related]
13. [Efficacy and safety in chronic hepatitis B adolescent patients with lamivudine therapy]. Lu WL, Xie DY, Yao JL, Yao GB, Cui ZY, Zhang DF, Wu L. Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):429-31. PubMed ID: 15268810 [Abstract] [Full Text] [Related]
15. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels. Yalçin K, Değertekin H, Kokoğlu OF, Ayaz C. Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116 [Abstract] [Full Text] [Related]
16. Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan. Chien RN, Liaw YF. Antivir Ther; 2006 Mar; 11(7):947-52. PubMed ID: 17302259 [Abstract] [Full Text] [Related]
19. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B]. Zhou HJ, Li SG, Wen FY, Yang XY, Wu JL, Tan B, Fu J. Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911 [Abstract] [Full Text] [Related]